Product Program year 2020 Source: CMS Open Payments

Rth258a_Beovu_Ophthalmology

Drug Ophthalmology

NDC 0078-0827-99

Open in the dashboard

General payments

$128,496

58 payments

Research payments

$37,539

1 payment

Through program year 2020, $128,496 in general payments and $37,539 in research payments were reported against Rth258a_Beovu_Ophthalmology (Ophthalmology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Amount Payments
2020 General $98,493 42
2020 Research $37,539 1
2019 General $30,003 16

Breakdown

Who paid General payments · program years 2019–2020
  1. Novartis Pharma AG $128,496 58 payments
Top recipients General payments · program year 2020
  1. Srinivas Sadda Ophthalmology · Pasadena, CA $16,989 17% · 11 payments
  2. Jeffrey Heier Retina Specialist · Boston, MA $13,070 13% · 4 payments
  3. Charles Wykoff Ophthalmology · Bellaire, TX $11,580 12% · 7 payments
  4. Arshad Khanani Ophthalmology · Reno, NV $11,321 11% · 5 payments
  5. Pravin Dugel Ophthalmology · Phoenix, AZ $9,845 10% · 3 payments

The top 5 of 13 recipients; each share is of general payments naming this product in 2020.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2020
  1. Ophthalmology $76,148 77% · 10 practitioners
  2. Retina Specialist Ophthalmology $22,345 23% · 3 practitioners

Each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2020
  1. Texas $28,380 29% · 3 recipients
  2. California $16,989 17% · 1 recipient
  3. Ohio $14,688 15% · 2 recipients
  4. Massachusetts $13,070 13% · 1 recipient
  5. Nevada $11,321 11% · 1 recipient

The top 5 of 10 states; each share is of general payments naming this product in 2020 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to RTH258A_BEOVU_OPHTHALMOLOGY
Billing code Providers Services Paid by Medicare
Injection, brolucizumab-dbll, 1 mg J0179 31 16,727 $4,289,134

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

58 general · 1 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record